Imukin (Recombinant Human Interferon Gamma 1b)

Interferon gamma binds to specific cell‑surface receptors, triggering the JAK‑STAT signaling pathway. This activation leads to increased expression of genes that boost macrophage microbicidal activity, enhance antigen presentation, and shift the immune response toward a Th1 profile, thereby improving pathogen clearance and influencing bone turnover.

The dosage of Imukin is individualized and determined by the prescribing clinician based on the patient’s condition, weight, and response. Healthcare providers follow approved prescribing information and adjust the regimen as needed; exact dosing details are not disclosed here.

Safety data for interferon gamma during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Imukin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

The primary alternative for chronic granulomatous disease is granulocyte transfusion or prophylactic antibiotics, while other cytokine therapies such as interferon alpha target different pathways. Imukin uniquely activates macrophages via the interferon gamma receptor, offering a distinct mechanism that directly addresses the underlying immune defect.

Imukin must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and never frozen or shaken. Prior to administration, the solution may need gentle mixing according to the manufacturer’s instructions.

Imukin is supplied as a sterile solution for injection and is administered subcutaneously. The healthcare professional reconstitutes the product if required, selects an appropriate injection site, and follows aseptic technique. Dosing intervals are set by the prescriber.

Serious adverse events include severe allergic reactions such as anaphylaxis, autoimmune hepatitis, significant reductions in blood cell counts (neutropenia, thrombocytopenia), and rare pulmonary complications like alveolar proteinosis. Patients should be monitored closely for these signs and seek immediate medical attention if they occur.

Imukin is contraindicated in individuals with known hypersensitivity to interferon gamma or any excipients in the formulation. It should also be avoided in patients with active, uncontrolled infections or severe autoimmune disease unless the prescribing physician determines that benefits outweigh the risks.